Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Zentalis Pharmaceuticals: Q2 Earnings Insights

  Zentalis Pharmaceuticals (NASDAQ:ZNTL) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
byBenzinga Insights
August 9, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

 

Zentalis Pharmaceuticals (NASDAQ:ZNTL) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM.

Here’s what investors need to know about the announcement.

Earnings

Zentalis Pharmaceuticals missed estimated earnings by 12.61%, reporting an EPS of $-1.34 versus an estimate of $-1.19.

Revenue was down $0 from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.1 which was followed by a 10.37% drop in the share price the next day.

 

Listen to the earnings announcement yourself by clicking here.

To track all earnings releases for Zentalis Pharmaceuticals visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

CBD Of Denver’s Success In Challenging Climate With Increase In Q4 Revenue

By Jelena Martinovic
December 28, 12:02 PM
CBD of Denver has reported strong fourth-quarter revenues of approximately $1.31m, with $1.13m generated by Luxora and $176,000 by Libra 9. The CBD company attributed its growth to a number of factors, including its partnership with EDEKA and the popularity of its Magic Lappen product, both of which increased sales across Germany. CBD of Denver also highlighted the success of Libra 9's attendance at trade shows, which boosted brand recognition and allowed the company to form several significant partnerships. Meanwhile, Luxora's expansion into the European CBD wholesale market was credited with contributing significantly to the company's growth. Following the German government's expected approval of relevant legislation, Luxora Solutions will expand further into the German market. Germany's decision on legalising marijuana, which was set to be made in December, has been delayed until next year.

CBDD